Location: Cleveland Clinic Main Campus
Bekris lab is focused on Alzheimer's Disease Biomarker Discovery and uses clinical and experimental approaches to demonstrate the feasibility of genetic and epigenetic factors underlying soluble protein expression as either potential early stage drug targets or early biomarkers of disease risk, progression and therapeutic outcomes.
Alzheimer's disease is a devastating progressive neurodegenerative disorder that impacts millions of people worldwide. It is is now regarded as a continuum of pathological changes that are defined by pathological Aβ and Tau accumulation in the brain with a long pre-symptomatic period of 10 to 20 years.
View publications for Lynn Bekris, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Bekris’ team found that patterns of sTREM2-related inflammatory activity were specific to Alzheimer’s disease stages.
With a new $4 million grant, Drs. Cheng, Bekris and Leverenz will develop and utilize artificial intelligence tools to identify novel drug targets and repurposable drugs for Alzheimer’s disease.
The multi-institution collaboration, which includes Dr. Bekris’ team, aims to accelerate research for Alzheimer’s disease and related dementias.
Dr. Bekris’ team has found that Alzheimer’s disease resilience may be modulated by interactions between a TNFRSF1B gene variant and the protein sTNFR2.
Dr. Bekris’s team will study the protein TREM2 as a biomarker of inflammation in pre-symptomatic and early symptomatic stages of Alzheimer’s disease.